Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26025745 | 1.00 | AOC3 (0.59) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL9577935 | 0.84 | AOC3 (0.57) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL10451736 | 0.80 | AOC3 (0.53) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL6464699 | 0.80 | AOC3 (0.57) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL112589 | 0.80 | AOC3 (0.57) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL9334567 | 0.80 | AOC3 (0.57) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL477440 | 0.80 | AOC3 (0.57) | AOC3LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL60356 | 0.79 | AOC3 (0.57) | AOC3LMNAKDM4EALDH1A1SLC6A4 | |
| SCHEMBL9683893 | 0.79 | AOC3 (0.57) | AOC3LMNAKDM4EALDH1A1SLC6A4 | |
| SCHEMBL8330705 | 0.79 | AOC3 (0.52) | AOC3LMNAADRA2AADRA2CHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1659154-B | Process for the preparation of amine stereoisomers | APSINTERM LLC | 2012-05-30 | — | — | CN | claimed |
| EP-1497272-A4 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM LLC (US) | 2007-02-07 | — | — | EP | claimed |
| US-7129378-B2 | Method of preparing amine stereoisomers | APSINTERM, LLC (US) | 2006-10-31 | — | — | US | claimed |
| CN-1659154-A | Process for the preparation of amine stereoisomers | APSINTERM LLC (US) | 2005-08-24 | — | — | CN | claimed |
| US-20050165240-A1 | Method of preparing amine stereoisomers | APSINTERM, LLC | 2005-07-28 | — | — | US | claimed |
| EP-1497272-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | Apsinterm, LLC. (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2003091207-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM, LLC. (US) | 2003-11-06 | — | — | WO | claimed |
| US-20250049036-A1 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2025-02-13 | — | — | US | disclosed |
| EP-4448494-A1 | NOVEL SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | PI Industries Ltd. (IN) | 2024-10-23 | — | — | EP | disclosed |
| EP-3541375-B1 | FACTOR XIIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023112056-A1 | NOVEL SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2023-06-22 | — | — | WO | disclosed |
| EP-3390355-B1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2022-12-28 | — | — | EP | disclosed |
| CN-110088094-A | The method for preparing the pure C9- acetal of alloisomerism | 巴斯夫欧洲公司 | 2019-08-02 | — | — | CN | disclosed |
| CN-1659154-A | Process for the preparation of amine stereoisomers | APSINTERM LLC (US) | 2005-08-24 | — | — | CN | disclosed |
| US-20050165240-A1 | Method of preparing amine stereoisomers | APSINTERM, LLC | 2005-07-28 | — | — | US | disclosed |
| WO-2005037828-A1 | NOVEL INHIBITORS OF DPP-IV, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2005-04-28 | — | — | WO | disclosed |
| EP-1497272-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | Apsinterm, LLC. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003091207-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM, LLC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-5367094-A | Hydrogenation for dehydroxylation of 2-amino-1-phenyl-1,3-propanediol in the presence of strong acid | YUKONG, LTD. (KR) | 1994-11-22 | — | — | US | disclosed |
| US-4261890-A | Substituted tetrahydrobenzazepines and tetrahydronaphthazepines and methods for their production | WARNER-LAMBERT COMPANY (US) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049036-A1 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | CBR3, C5, CBR1 | AOC3 2227/4885LMNA 3367/4885ADRA2A 2890/4885 |
| US-20050165240-A1 | Method of preparing amine stereoisomers | SRM, TST, SMOX | AOC3 353/4885LMNA 3417/4885ADRA2A 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.